Citigroup
OKUR

Citigroup’s OnKure Therapeutics OKUR Stock Holding History

Citigroup’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4 Sell
1
-3,728
-100% -$11.5K ﹤0.01% 5794
2025
Q4 		$10.8K Buy
3,729
+405
+12% +$1.21K ﹤0.01% 5033
2025
Q3 		$9.14K Buy
3,324
+3,073
+1,224% +$7.61K ﹤0.01% 5051
2025
Q2 		$600 Buy
251
+61
+32% +$160 ﹤0.01% 5434
2025
Q1 		$818 Buy
190
+88
+86% +$495 ﹤0.01% 5374
2024
Q4 		$877 Sell
102
-253
-71% -$3.83K ﹤0.01% 5604
2024
Q3 		$6.04K Sell
355
-512
-59% -$7.57K ﹤0.01% 5337
2024
Q2 		$13.1K Buy
867
+263
+44% +$4.46K ﹤0.01% 5092
2024
Q1 		$10K Buy
604
+324
+116% +$5.34K ﹤0.01% 5199
2023
Q4 		$4.47K Buy
280
+227
+428% +$14.1K ﹤0.01% 5350
2023
Q3 		$4.04K Sell
53
-235
-82% -$16K ﹤0.01% 4770
2023
Q2 		$18.9K Buy
+288
New +$23.2K ﹤0.01% 4969
2022
Q4 		– Sell
-750
Closed -$25K – 5998
2022
Q3 		$25K Sell
750
-38
-5% -$1.25K ﹤0.01% 4663
2022
Q2 		$21K Buy
788
+712
+937% +$16.6K ﹤0.01% 4986
2022
Q1 		$2K Sell
76
-187
-71% -$10.5K ﹤0.01% 6103
2021
Q4 		$22K Buy
263
+147
+127% +$10.8K ﹤0.01% 5363
2021
Q3 		$9K Buy
116
+86
+287% +$7.3K ﹤0.01% 5504
2021
Q2 		$3K Buy
+30
New +$3.35K ﹤0.01% 5939

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FCMV
Foresite Capital Management VI Larkspur, California $460M AUM 261.77% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Citigroup's OKUR Position: Q1 2026 in Review

Citigroup reduced its OnKure Therapeutics (OKUR) stake by 100% in Q1 2026, selling an estimated $11.5K and leaving 1 share worth $4. The position accounts for ﹤0.01% of the portfolio, ranked #5794.

Citigroup first reported a position in OKUR in Q2 2021 and has held it in 18 quarters since. The position peaked at $25K in Q3 2022. 51 funds tracked by Wall St. Rank hold OKUR as of Q1 2026.

  • Citigroup held 1 share of OnKure Therapeutics worth $4 as of Q1 2026.
  • Citigroup sold 3,728 OnKure Therapeutics shares in Q1 2026, an estimated $11.5K.
  • OnKure Therapeutics made up ﹤0.01% of Citigroup's portfolio in Q1 2026, its #5794 holding.
  • Citigroup first reported a position in OnKure Therapeutics in Q2 2021 and has held it in 18 quarters since.
  • Citigroup's OnKure Therapeutics position peaked at $25K in Q3 2022.
  • 51 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q1 2026.

Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.